Related Experiment Video
Updated: Jul 31, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
13.0K
Derisking Phase II Clinical Trials in Heart Failure: A Position Paper from JACC: Basic to Translational Science and
Douglas L Mann1, G Michael Felker2, Ellis F Unger3
1Washington University School of Medicine, St. Louis, Missouri, USA.
JACC. Basic to Translational Science
|May 28, 2025
Summary
Phase II clinical trials are crucial for drug development, establishing proof of concept and evaluating safety. However, these trials have limitations and cannot fully predict later-stage outcomes for new therapies.
Area of Science:
- Cardiovascular Medicine
- Clinical Pharmacology
- Drug Development
Background:
- Phase II clinical trials are pivotal in drug development, offering essential data for decision-making.
- Key objectives include establishing proof of concept, evaluating pharmacokinetics, pharmacodynamics, safety, and dose-response relationships.
Purpose of the Study:
- To examine the value and constraints of Phase II programs in drug development.
- To provide insights for investigators and sponsors to mitigate risks in go/no-go decisions for therapeutic candidates.
Main Methods:
- Review of Phase II clinical trial methodologies and objectives.
- Analysis of limitations inherent in Phase II studies.
- Case examples from heart failure trials are utilized.
Main Results:
- Phase II trials provide critical proof of concept and safety data.
- These trials inform go/no-go decisions for advancing drug candidates.
- Phase II outcomes do not fully predict Phase III success.
Conclusions:
- Understanding the limitations of Phase II trials is essential for accurate risk assessment.
- Strategic planning of Phase II programs can improve the success rate of drug development.
- This paper aims to derisk go/no-go decisions by analyzing Phase II trial value and constraints.
More Related Videos
Related Concept Videos
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...